home / stock / rapt / rapt news

RAPT News and Press, RAPT Therapeutics Inc. From 11/06/25

Stock Information
Company Name: RAPT Therapeutics Inc.
Stock Symbol: RAPT
Market: NASDAQ
Website: rapt.com
Menu
RAPT RAPT Quote RAPT Short RAPT News RAPT Articles RAPT Message Board
Get RAPT Alerts

News, Short Squeeze, Breakout and More Instantly...
RAPT - RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $25...
RAPT - RAPT Price Target Alert: $72.00. Issued by Wells Fargo

2025-11-03 06:37:31 ET from Wells Fargo issued a price target of $72.00 for RAPT on 2025-11-03 11:07:22. The adjusted price target was set to $72.00. At the time of the announcement, RAPT was trading at $30.21. The overall price target consensus is at $44.60 with high pr...

RAPT - RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 (GLOBE ...

RAPT - RAPT Therapeutics prices equity offering at $30 per share

2025-10-22 02:41:39 ET More on RAPT Therapeutics RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous ...
RAPT - RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory an...

RAPT - RAPT Therapeutics announces proposed public offering

2025-10-21 16:17:11 ET More on RAPT Therapeutics RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria - Slideshow RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous ...

RAPT - RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory an...
RAPT - RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

2025-10-20 17:05:38 ET RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: RAPT Therapeutics, Inc. (RAPT) Discusses Top...

RAPT - VENU Sets the Stage, Biotechs Rally, and AI-Powered Fintech

2025-10-20 12:41:14 ET DENVER, Colo., Oct 20, 2025 ( 247marketnews.com )- Wall Street is dialing into a mix of bold biotech breakthroughs, AI-powered real estate finance, and a Live Music Innovator that could redraw the sentertainment map. Here’s what’s driving the action ...

RAPT - RAPT Therapeutics jumps on mid-stage data for urticaria candidate

2025-10-20 11:03:00 ET More on RAPT Therapeutics Seeking Alpha’s Quant Rating on RAPT Therapeutics Historical earnings data for RAPT Therapeutics Financial information for RAPT Therapeutics Read the full article on Seeking Alpha For further det...
Previous 10 Next 10